top of page

【Portfolio】维眸生物宣布成立科学顾问委员会并召开首次科学顾问委员会会议及专家研讨会

维眸-VVB logo.jpg

​​文章来源:维眸生物 http://www.vivavisionbio.com/

2021年12月1日

本次会议上,SAB成员孙兴怀教授、陈有信教授、Louis Tong教授及专家团队徐建江教授、接英教授、洪佳旭教授共同参与。SAB成员David Boyer博士因为时差原因缺席本次研讨会。与会的专家们主要围绕公司开展的多条研发管线项目进行了深入讨论,讨论内容则涵盖了科学支撑依据、未满足的临床需求及国内外临床现状、最新研发数据和未来管线布局等方面。SAB成员及专家团队对于公司丰富的研发管线、研发项目的差异化、作用机制的多样性以及关键项目的快速推进表达了高度认可。

维眸创始人兼首席执行官沈旺博士表示:

 

" 科学顾问委员会由国内外眼科医学领域享有声望的顶尖专家组成,他们是中、美、新加坡眼科临床研究的带头人,科学顾问委员会的成立将帮助维眸更清晰的看到未满足的临床需求,并以他们专业前沿的临床研究理念帮助我们丰富和强化创新的产品管线。

我们非常荣幸能够邀请到四位专家加入维眸生物的科学顾问委员会,期待在今后同维眸团队及其他临床研究者紧密协作中,能共同解决在创新发展过程中遇到的问题,为公司研发管线的全球开发提供更多的临床支持,为眼科疾病患者创造更多治愈的可能性,为改善人类的生活质量,贡献积极的力量。"

 

维眸生物科学顾问委员会专家成员简介

 

  • 孙兴怀 教授, SAB主席

孙兴怀教授任复旦大学医学院、附属眼耳鼻喉科医院教授 青光眼与视神经疾病学科主任,眼科学与视觉科学系主任,中华医学会眼科学分会候任主任委员 五官科医院前院长(2005-2016) 担任多个学术机构主委,管理委员会成员;获得多项荣誉 青光眼、视觉,视神经专家,发表300多篇论文,主编专著8本(英文1本)、丛书2套、科普书4本。

 

孙教授主要的研究方向为致力于青光眼视神经病变及相关视觉损害的发病机制与神经保护、视网膜视神经疾病导致的低视力视觉可塑性及重建研究。将神经科学与眼科临床问题紧密结合,从分子生物、形态与功能、表观遗传、干细胞技术等多个角度,围绕视网膜、外侧膝状体和视觉皮质三个层面,系统研究不同类型视觉神经系统损害的发生、发展,以及可能的视功能保护、重塑机制与措施。

 

 

  • 陈有信 教授, SAB成员

 

北京协和医院眼科主任,教授,博士生导师

著名眼底疾病专家,老年黄斑变性、高度近视眼底病变、糖尿病视网膜病变、黄斑水肿等领域享有崇高声誉

中华医学会眼科分会秘书长,总干事,中国医师协会眼科医师分会副总干事兼秘书

获得国家科技进步二等奖、中华眼科学会奖、中国优秀眼科医师奖,亚太眼科学会Distinguished Service Award,等很多奖项。

 

陈教授在脉络膜血管造影及疑难眼底病的诊治方面积累了丰富经验。近年开展了光动力学治疗为脉络膜新生血管的治疗提供了新的治疗手段,取得了很好的效果。在国内率先开展脉络膜血管的临床及研究。

 

 

  • Prof. David S. Boyer, SAB成员

World-renowned clinician, surgeon, and educator. Senior Partner at Retina-Vitreous Associates Medical Group (LA area), adjunct Clinical Professor of Ophthalmology, USC/Keck School of Medicine. One of the leading retinal clinical researchers in the US for AMD and DME; and a widely-published author and avid lecturer

 

  • Prof. Louis Tong, SAB成员

Professor, Duke-National University of Singapore Medical School; Corneal and External Eye Disease Department. Principal Clinician Scientist and head of ocular surface research group at Singapore Eye Research Institute, Senior Consultant, Singapore National Eye Center 

This website is for informational purposes only and does not constitute an offer to sell, a solicitation to buy, or a recommendation for any security; nor does it constitute an offer to provide investment advisory or other services by Viva Ventures Biotech Fund or any of our affiliates. Nothing contained on the website constitutes investment advice or offers any opinion with respect to the suitability of any security, and the views expressed on this website should not be taken as advice to buy, sell, or hold any security or as an endorsement of any security or company. In preparing the information contained in this website, Viva Ventures Biotech has not taken into account the investment needs, objectives, and financial circumstances of any particular investor, and investments and companies referenced may not be suitable for all investors. Any views expressed on this website by Viva Ventures biotech were prepared based upon information, believed to be reliable, available to it at the time such views were written. Viva Ventures Biotech makes no guarantees as to their accuracy or completeness. All information is subject to change and may quickly become unreliable for various reasons, including changes in market conditions or economic circumstances. By accessing this website, the reader agrees that he/she not copy, reproduce, republish, upload, post, transmit, alter, or distribute in any way material from this website in any manner inconsistent with the purposes for which it is offered without the prior written consent of Viva Ventures Biotech.

bottom of page